Aprecia announced that the Food and Drug Administration (FDA) has approved SPRITAM® (levetiracetam) tablets as adjunctive therapy in the treatment of partial onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in people with epilepsy. Spritam is the first three dimensional (3D) printed drug product approved by the FDA.
More details about these uses, including the approved age ranges in children, are described in the “Levetiracetam oral tablets uses” section below. * For this use, levetiracetam is prescribed along ...